Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
27/05/2026 07:35
BRIEF-Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia May 27 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement on the Budapest Stock Exchange:
AGREES WITH ACRUX ON EXTENSION OF ITS LICENSE AGREEMENT DATED 2013 RELATING TO TRANSDERMAL ESTRADIOL SPRAY LENZETTO TO AUSTRALIAN MARKET
AMENDED AGREEMENT PROVIDES RICHTER EXCLUSIVE COMMERCIALIZATION RIGHTS FOR THE AUSTRALIAN MARKET
RICHTER SAYS ACRUX WILL RECEIVE TOTAL PAYMENTS OF AUD 5.4 MILLION OVER THE COMING PERIOD
Source text: [ID:]
Further company coverage: GDRB.BU
(Reporting by Krisztina Than)
((Krisztina.Than@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab